<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01989468</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457F2318</org_study_id>
    <secondary_id>2013-004002-25</secondary_id>
    <nct_id>NCT01989468</nct_id>
  </id_info>
  <brief_title>24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis</brief_title>
  <official_title>A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Psoriatic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide 24 - 52 week efficacy, safety and tolerability data,
      and up to 3-year efficacy, safety and tolerability data in subjects with active Psoriatic
      Arthritis despite current or previous nonsteroidal anti-inflammatory drug (NSAID),
      disease-modifying antirheumatic drug (DMARD) therapy and/or previous anti-tumor necrosis
      factor alpha (TNFÎ±) therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 10, 2014</start_date>
  <completion_date type="Actual">March 28, 2018</completion_date>
  <primary_completion_date type="Actual">May 27, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients Achieving American College of Rheumatology 20 (ACR20) Response Criteria on Secukinumab Versus Placebo at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>A patient will be considered as improved according the ACR20 criteria if she/he has at least 20% decrease in the swollen and tender joint count, and at least 20% improvements in 3 of the following 5 criteria: physical disability on the Health Assessment Questionnaire; pain score on a visual analog scale; patient global assessment; physician global assessment; and acute phase reactant [either erythrocyte sedimentation rate (ESR) or high sensitivity C-reactive protein (hsCRP)]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Achieving American College of Rheumatology 50 (ACR50) Response Criteria on Secukinumab Versus Placebo at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>A patient will be considered as improved according the ACR50 criteria if she/he has at least 50% decreases in the swollen and tender joint count, and at least 50% improvements in 3 of the following 5 criteria: physical disability on the Health Assessment Questionnaire; pain score on a visual analog scale; patient global assessment; physician global assessment; and acute phase reactant [either erythrocyte sedimentation rate (ESR) or high sensitivity C-reactive protein (hsCRP)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score for 28 Joints (DAS28-CRP) (Utilizing hsCRP) in Subjects Treated With Secukinumab Versus Placebo at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>DAS28-CRP is a measure of disease activity based on 28-Swollen and Tender Joint Count [proximal interphalangeal joints (10 joints) metacarpophalangeal joints (10) wrists (2) elbows (2) shoulders (2) knees (2)], CRP, and the Patient's Global Assessment of disease activity. Values range from 2.0 to 10.0 where higher values mean a higher disease activity. DAS28-CRP &lt; 2.6 is interpreted as remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Achieving a Psoriatic Area and Severity Index 75 (PASI75) Response in Subjects on Secukinumab Versus Placebo at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>PASI takes into account the extent of the disease, as well as the severity of erythema, scaling, and thickness in different body areas affected by psoriasis. A PASI75 represents an improvement in the PASI score of at least 75% as compared with baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physical Function Component of the Short-form Health Survey (SF-36-PCS) in Subjects Treated With Secukinumab Versus Placebo at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>SF-36 is a 36 item questionnaire which measures Quality of Life across eight domains, which are both physically and emotionally based. Two overall summary scores, the Physical Component Summary (PCS) and Mental Component Summary (MCS) can be computed. In this study, SF-36 PCS is used to assess improvement from baseline of at least one dose of secukinumab versus placebo. The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving a Psoriatic Area and Severity Index 90 (PASI90) Response in Subjects Treated With Secukinumab Versus Placebo at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>PASI takes into account the extent of the disease, as well as the severity of erythema, scaling, and thickness in different body areas affected by psoriasis. A PASI90 represents an improvement in the PASI score of at least 90% as compared with baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI Score) in Subjects Treated With Secukinumab Versus Placebo at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>The HAQ measures physical disability and functional status. It has 4 dimensions: disability, pain, drug side effects and dollar costs. In this trial, only the disability dimension was used. The disability dimension consists of 20 multiple choice items concerning difficulty in performing 8 common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and activities. Participants choose from four response categories: 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty) and 3 (unable to do). Within each of the 8 categories, only the item indicating the most severe impairment contributes to the category score. The HAQ score is calculated by summing the computed scores for each category and dividing by the number of categories answered. It ranges from 0 (without any difficulty) to 3 (unable to do). A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Dactylitis at Week 24 in the Subset of Patients Who Had Dactylitis at Baseline</measure>
    <time_frame>Week 24</time_frame>
    <description>The presence of dactylitis was assessed by dactylitis count (number of fingers and toes with dactylitis, with a range of 0-20). If dactylitis is present with any finger or toe, the patient is counted as a patient with dactylitis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Enthesitis at Week 24 in the Subset of Patients Who Had Enthesitis at Baseline</measure>
    <time_frame>Week 24</time_frame>
    <description>The presence of Enthesitis was assessed using a validated enthesitis index that uses 6 sites for evaluation of enthesitis: lateral epicondyle humerus L + R, proximal achilles L + R and medial condyle femur. If enthesitis is present at any of the 6 sites, the subject is counted as a subject with enthesitis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by Primary System Organ Class (SOC)</measure>
    <time_frame>From first dose of study treatment to last study visit, up to 3 years</time_frame>
    <description>Analysis of frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">414</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Secukinumab (AIN457) 150 mg s.c.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Secukinumab (AIN457) 300 mg s.c.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>Secukinumab 150 mg provided in a 1 mL autoinjector (1 autoinjector for 150 mg dose, 2 autoinjectors for 300 mg dose)</description>
    <arm_group_label>Secukinumab (AIN457) 150 mg s.c.</arm_group_label>
    <arm_group_label>Secukinumab (AIN457) 300 mg s.c.</arm_group_label>
    <other_name>Secukinumab 150 mg</other_name>
    <other_name>Secukinumab 300 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Secukinumab placebo provided in 1 mL autoinjector</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Psoriatic Arthritis (PsA) classified by ClASsification criteria for
             Psoriatic ARthritis (CASPAR) criteria.

          -  Rheumatoid factor and anti-cyclic citrullinated peptide (CCP) antibodies negative.

          -  Diagnosis of active plaque psoriasis or nail changes consistent with psoriasis.

          -  Inadequate control of symptoms with NSAID.

        Exclusion Criteria:

          -  Chest X-ray or chest magnetic resonance imaging (MRI) with evidence of ongoing
             infectious or malignant process.

          -  Subjects taking high potency opioid analgesics.

          -  Previous exposure to secukinumab or other biologic drug directly targeting
             interleukin-17 (IL-17) or IL-17 receptor.

          -  Ongoing use of prohibited psoriasis treatments / medications.

          -  Subjects who have ever received biologic immunomodulating agents except for those
             targeting TNFÎ±.

          -  Previous treatment with any cell-depleting therapies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <zip>42101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <zip>07728</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maroochydore</city>
        <state>Queensland</state>
        <zip>4558</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malvern East</city>
        <state>Victoria</state>
        <zip>3145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1413</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1505</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 3M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trois Rivieres</city>
        <state>Quebec</state>
        <zip>G8Z 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruntal</city>
        <state>Czech Republic</state>
        <zip>792 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 2</city>
        <state>Czech Republic</state>
        <zip>128 50</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uherske Hradiste</city>
        <state>Czech Republic</state>
        <zip>686 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aachen</city>
        <zip>52064</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chemnitz</city>
        <zip>09130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91056</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gommern</city>
        <zip>39245</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hildesheim</city>
        <zip>31134</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zerbst</city>
        <zip>39261</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3079 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caguas</city>
        <zip>00725</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rostov on Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saratov</city>
        <zip>410053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sestroretsk</city>
        <zip>197706</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Coruna</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fribourg</city>
        <zip>1708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Gallen</city>
        <zip>CH 9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salford</city>
        <state>Manchester</state>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cannock</city>
        <state>Staffordshire</state>
        <zip>WS11 2XY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stoke on Trent</city>
        <state>Staffordshire</state>
        <zip>ST6 7AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barnsley</city>
        <zip>S75 2EP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eastbourne</city>
        <zip>BN21 2UD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Harrogate</city>
        <zip>HG2 7SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torquay</city>
        <zip>TQ2 7AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tyne And Wear</city>
        <zip>NE29 8NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Norway</country>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>November 7, 2013</study_first_submitted>
  <study_first_submitted_qc>November 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2013</study_first_posted>
  <results_first_submitted>February 25, 2019</results_first_submitted>
  <results_first_submitted_qc>April 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 16, 2019</results_first_posted>
  <last_update_submitted>April 15, 2019</last_update_submitted>
  <last_update_submitted_qc>April 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriatic arthritis</keyword>
  <keyword>AIN457</keyword>
  <keyword>PsA</keyword>
  <keyword>ACR</keyword>
  <keyword>CASPAR</keyword>
  <keyword>PASDAS</keyword>
  <keyword>secukinumab</keyword>
  <keyword>autoinjector</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were randomized to 1 of 3 treatment arms (1:1:1) and planned to be treated for 156 weeks. Placebo non-responders had the option to be re-randomized at Week 16 and placebo responders had the option to be re-randomized at Week 24. Thus, of the 137 original placebo patients 64 were re-randomized to AIN457 150 mg and 65 to AIN457 300 mg.</recruitment_details>
      <pre_assignment_details>A screening period (SCR) running up to 10 weeks before randomization was used to assess eligibility.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AIN457 150 mg</title>
          <description>1 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
        </group>
        <group group_id="P2">
          <title>AIN457 300 mg</title>
          <description>2 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
        </group>
        <group group_id="P3">
          <title>Placebo_AIN457 150 mg</title>
          <description>Placebo switch to Secukinumab/AIN457 150 mg</description>
        </group>
        <group group_id="P4">
          <title>Placebo_AIN457 300 mg</title>
          <description>Placebo switch to Secukinumab/AIN457 300 mg</description>
        </group>
        <group group_id="P5">
          <title>Placebo Not Rerandomized</title>
          <description>Matching Placebo at Beseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="138"/>
                <participants group_id="P2" count="139"/>
                <participants group_id="P3" count="64"/>
                <participants group_id="P4" count="65"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="49"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical Problems</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Guardian Decision</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AIN457 150 mg</title>
          <description>1 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
        </group>
        <group group_id="B2">
          <title>AIN457 300 mg</title>
          <description>2 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Matching Placebo at Beseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="138"/>
            <count group_id="B2" value="139"/>
            <count group_id="B3" value="137"/>
            <count group_id="B4" value="414"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="367"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="227"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="133"/>
                    <measurement group_id="B4" value="392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients Achieving American College of Rheumatology 20 (ACR20) Response Criteria on Secukinumab Versus Placebo at Week 24</title>
        <description>A patient will be considered as improved according the ACR20 criteria if she/he has at least 20% decrease in the swollen and tender joint count, and at least 20% improvements in 3 of the following 5 criteria: physical disability on the Health Assessment Questionnaire; pain score on a visual analog scale; patient global assessment; physician global assessment; and acute phase reactant [either erythrocyte sedimentation rate (ESR) or high sensitivity C-reactive protein (hsCRP)]</description>
        <time_frame>Week 24</time_frame>
        <population>The Full Analysis Set (FAS) based on Primary Analysis, which consisted of all participants with an observed value, was considered.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>1 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>2 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo at Beseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Achieving American College of Rheumatology 20 (ACR20) Response Criteria on Secukinumab Versus Placebo at Week 24</title>
          <description>A patient will be considered as improved according the ACR20 criteria if she/he has at least 20% decrease in the swollen and tender joint count, and at least 20% improvements in 3 of the following 5 criteria: physical disability on the Health Assessment Questionnaire; pain score on a visual analog scale; patient global assessment; physician global assessment; and acute phase reactant [either erythrocyte sedimentation rate (ESR) or high sensitivity C-reactive protein (hsCRP)]</description>
          <population>The Full Analysis Set (FAS) based on Primary Analysis, which consisted of all participants with an observed value, was considered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Achieving American College of Rheumatology 50 (ACR50) Response Criteria on Secukinumab Versus Placebo at Week 24</title>
        <description>A patient will be considered as improved according the ACR50 criteria if she/he has at least 50% decreases in the swollen and tender joint count, and at least 50% improvements in 3 of the following 5 criteria: physical disability on the Health Assessment Questionnaire; pain score on a visual analog scale; patient global assessment; physician global assessment; and acute phase reactant [either erythrocyte sedimentation rate (ESR) or high sensitivity C-reactive protein (hsCRP)]</description>
        <time_frame>Week 24</time_frame>
        <population>The Full Analysis Set (FAS) based on Primary Analysis, which consisted of all participants with an observed value, was considered.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>1 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>2 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo at Beseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Achieving American College of Rheumatology 50 (ACR50) Response Criteria on Secukinumab Versus Placebo at Week 24</title>
          <description>A patient will be considered as improved according the ACR50 criteria if she/he has at least 50% decreases in the swollen and tender joint count, and at least 50% improvements in 3 of the following 5 criteria: physical disability on the Health Assessment Questionnaire; pain score on a visual analog scale; patient global assessment; physician global assessment; and acute phase reactant [either erythrocyte sedimentation rate (ESR) or high sensitivity C-reactive protein (hsCRP)]</description>
          <population>The Full Analysis Set (FAS) based on Primary Analysis, which consisted of all participants with an observed value, was considered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score for 28 Joints (DAS28-CRP) (Utilizing hsCRP) in Subjects Treated With Secukinumab Versus Placebo at Week 24</title>
        <description>DAS28-CRP is a measure of disease activity based on 28-Swollen and Tender Joint Count [proximal interphalangeal joints (10 joints) metacarpophalangeal joints (10) wrists (2) elbows (2) shoulders (2) knees (2)], CRP, and the Patient's Global Assessment of disease activity. Values range from 2.0 to 10.0 where higher values mean a higher disease activity. DAS28-CRP &lt; 2.6 is interpreted as remission.</description>
        <time_frame>Week 24</time_frame>
        <population>The Full Analysis Set (FAS) based on Primary Analysis, which consisted of all participants with an observed value, was considered.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>1 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>2 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo at Beseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score for 28 Joints (DAS28-CRP) (Utilizing hsCRP) in Subjects Treated With Secukinumab Versus Placebo at Week 24</title>
          <description>DAS28-CRP is a measure of disease activity based on 28-Swollen and Tender Joint Count [proximal interphalangeal joints (10 joints) metacarpophalangeal joints (10) wrists (2) elbows (2) shoulders (2) knees (2)], CRP, and the Patient's Global Assessment of disease activity. Values range from 2.0 to 10.0 where higher values mean a higher disease activity. DAS28-CRP &lt; 2.6 is interpreted as remission.</description>
          <population>The Full Analysis Set (FAS) based on Primary Analysis, which consisted of all participants with an observed value, was considered.</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.24" spread="0.095"/>
                    <measurement group_id="O2" value="-1.56" spread="0.093"/>
                    <measurement group_id="O3" value="-0.64" spread="0.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Achieving a Psoriatic Area and Severity Index 75 (PASI75) Response in Subjects on Secukinumab Versus Placebo at Week 24</title>
        <description>PASI takes into account the extent of the disease, as well as the severity of erythema, scaling, and thickness in different body areas affected by psoriasis. A PASI75 represents an improvement in the PASI score of at least 75% as compared with baseline.</description>
        <time_frame>Week 24</time_frame>
        <population>The Full Analysis Set (FAS) based on Primary Analysis, which consisted of all participants with an observed value, was considered.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>1 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>2 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo at Beseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Achieving a Psoriatic Area and Severity Index 75 (PASI75) Response in Subjects on Secukinumab Versus Placebo at Week 24</title>
          <description>PASI takes into account the extent of the disease, as well as the severity of erythema, scaling, and thickness in different body areas affected by psoriasis. A PASI75 represents an improvement in the PASI score of at least 75% as compared with baseline.</description>
          <population>The Full Analysis Set (FAS) based on Primary Analysis, which consisted of all participants with an observed value, was considered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physical Function Component of the Short-form Health Survey (SF-36-PCS) in Subjects Treated With Secukinumab Versus Placebo at Week 24</title>
        <description>SF-36 is a 36 item questionnaire which measures Quality of Life across eight domains, which are both physically and emotionally based. Two overall summary scores, the Physical Component Summary (PCS) and Mental Component Summary (MCS) can be computed. In this study, SF-36 PCS is used to assess improvement from baseline of at least one dose of secukinumab versus placebo. The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.</description>
        <time_frame>Week 24</time_frame>
        <population>The Full Analysis Set (FAS) based on Primary Analysis, which consisted of all participants with an observed value, was considered.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>1 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>2 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo at Beseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physical Function Component of the Short-form Health Survey (SF-36-PCS) in Subjects Treated With Secukinumab Versus Placebo at Week 24</title>
          <description>SF-36 is a 36 item questionnaire which measures Quality of Life across eight domains, which are both physically and emotionally based. Two overall summary scores, the Physical Component Summary (PCS) and Mental Component Summary (MCS) can be computed. In this study, SF-36 PCS is used to assess improvement from baseline of at least one dose of secukinumab versus placebo. The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.</description>
          <population>The Full Analysis Set (FAS) based on Primary Analysis, which consisted of all participants with an observed value, was considered.</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mental Component Summary (MCS)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="130"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="0.837"/>
                    <measurement group_id="O2" value="4.41" spread="0.822"/>
                    <measurement group_id="O3" value="-0.10" spread="1.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Summary (PCS)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="130"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.42" spread="0.600"/>
                    <measurement group_id="O2" value="6.46" spread="0.590"/>
                    <measurement group_id="O3" value="2.94" spread="0.830"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving a Psoriatic Area and Severity Index 90 (PASI90) Response in Subjects Treated With Secukinumab Versus Placebo at Week 24</title>
        <description>PASI takes into account the extent of the disease, as well as the severity of erythema, scaling, and thickness in different body areas affected by psoriasis. A PASI90 represents an improvement in the PASI score of at least 90% as compared with baseline.</description>
        <time_frame>Week 24</time_frame>
        <population>The Full Analysis Set (FAS) based on Primary Analysis, which consisted of all participants with an observed value, was considered.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>1 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>2 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo at Beseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving a Psoriatic Area and Severity Index 90 (PASI90) Response in Subjects Treated With Secukinumab Versus Placebo at Week 24</title>
          <description>PASI takes into account the extent of the disease, as well as the severity of erythema, scaling, and thickness in different body areas affected by psoriasis. A PASI90 represents an improvement in the PASI score of at least 90% as compared with baseline.</description>
          <population>The Full Analysis Set (FAS) based on Primary Analysis, which consisted of all participants with an observed value, was considered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI Score) in Subjects Treated With Secukinumab Versus Placebo at Week 24</title>
        <description>The HAQ measures physical disability and functional status. It has 4 dimensions: disability, pain, drug side effects and dollar costs. In this trial, only the disability dimension was used. The disability dimension consists of 20 multiple choice items concerning difficulty in performing 8 common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and activities. Participants choose from four response categories: 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty) and 3 (unable to do). Within each of the 8 categories, only the item indicating the most severe impairment contributes to the category score. The HAQ score is calculated by summing the computed scores for each category and dividing by the number of categories answered. It ranges from 0 (without any difficulty) to 3 (unable to do). A negative change from baseline indicates improvement.</description>
        <time_frame>Week 24</time_frame>
        <population>The Full Analysis Set (FAS) based on Primary Analysis, which consisted of all participants with an observed value, was considered.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>1 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>2 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo at Beseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI Score) in Subjects Treated With Secukinumab Versus Placebo at Week 24</title>
          <description>The HAQ measures physical disability and functional status. It has 4 dimensions: disability, pain, drug side effects and dollar costs. In this trial, only the disability dimension was used. The disability dimension consists of 20 multiple choice items concerning difficulty in performing 8 common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and activities. Participants choose from four response categories: 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty) and 3 (unable to do). Within each of the 8 categories, only the item indicating the most severe impairment contributes to the category score. The HAQ score is calculated by summing the computed scores for each category and dividing by the number of categories answered. It ranges from 0 (without any difficulty) to 3 (unable to do). A negative change from baseline indicates improvement.</description>
          <population>The Full Analysis Set (FAS) based on Primary Analysis, which consisted of all participants with an observed value, was considered.</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.043"/>
                    <measurement group_id="O2" value="-0.38" spread="0.042"/>
                    <measurement group_id="O3" value="-0.17" spread="0.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Dactylitis at Week 24 in the Subset of Patients Who Had Dactylitis at Baseline</title>
        <description>The presence of dactylitis was assessed by dactylitis count (number of fingers and toes with dactylitis, with a range of 0-20). If dactylitis is present with any finger or toe, the patient is counted as a patient with dactylitis.</description>
        <time_frame>Week 24</time_frame>
        <population>The Dactylitis subset of the Full Analysis Set (FAS) based on Primary Analysis, which consisted of all participants with an observed value at Baseline and post-basline, was considered.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>1 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>2 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo at Beseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Dactylitis at Week 24 in the Subset of Patients Who Had Dactylitis at Baseline</title>
          <description>The presence of dactylitis was assessed by dactylitis count (number of fingers and toes with dactylitis, with a range of 0-20). If dactylitis is present with any finger or toe, the patient is counted as a patient with dactylitis.</description>
          <population>The Dactylitis subset of the Full Analysis Set (FAS) based on Primary Analysis, which consisted of all participants with an observed value at Baseline and post-basline, was considered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Enthesitis at Week 24 in the Subset of Patients Who Had Enthesitis at Baseline</title>
        <description>The presence of Enthesitis was assessed using a validated enthesitis index that uses 6 sites for evaluation of enthesitis: lateral epicondyle humerus L + R, proximal achilles L + R and medial condyle femur. If enthesitis is present at any of the 6 sites, the subject is counted as a subject with enthesitis.</description>
        <time_frame>Week 24</time_frame>
        <population>The Enthesitis subset of the Full Analysis Set (FAS) based on Primary Analysis, which consisted of all participants with an observed value at Baseline and post-basline, was considered.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>1 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>2 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo at Beseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Enthesitis at Week 24 in the Subset of Patients Who Had Enthesitis at Baseline</title>
          <description>The presence of Enthesitis was assessed using a validated enthesitis index that uses 6 sites for evaluation of enthesitis: lateral epicondyle humerus L + R, proximal achilles L + R and medial condyle femur. If enthesitis is present at any of the 6 sites, the subject is counted as a subject with enthesitis.</description>
          <population>The Enthesitis subset of the Full Analysis Set (FAS) based on Primary Analysis, which consisted of all participants with an observed value at Baseline and post-basline, was considered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by Primary System Organ Class (SOC)</title>
        <description>Analysis of frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC).</description>
        <time_frame>From first dose of study treatment to last study visit, up to 3 years</time_frame>
        <population>Safety Set, based on Final Analysis. All subjects who took at least one dose of study treatment during the treatment period. A subject with multiple adverse events within a primary system organ class was counted only once in the total row. Deaths up to 28 days after the last dose are included. Only descriptive analysis done.</population>
        <group_list>
          <group group_id="O1">
            <title>Any AIN457 150 mg</title>
            <description>Any patients exposed to AIN457 150 mg</description>
          </group>
          <group group_id="O2">
            <title>Any AIN457 300 mg</title>
            <description>Any patients exposed to AIN457 300 mg</description>
          </group>
          <group group_id="O3">
            <title>Any AIN457</title>
            <description>Any patients exposed to AIN457</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching Placebo at Beseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by Primary System Organ Class (SOC)</title>
          <description>Analysis of frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC).</description>
          <population>Safety Set, based on Final Analysis. All subjects who took at least one dose of study treatment during the treatment period. A subject with multiple adverse events within a primary system organ class was counted only once in the total row. Deaths up to 28 days after the last dose are included. Only descriptive analysis done.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="406"/>
                <count group_id="O4" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs by Primary System Organ Class (SOC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176"/>
                    <measurement group_id="O2" value="230"/>
                    <measurement group_id="O3" value="363"/>
                    <measurement group_id="O4" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs by Primary System Organ Class (SOC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="76"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths by Primary System Organ Class (SOC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Adverse Events (AEs) are reported in this record from date of First Patient First Treatment (FPFT) until end of treatment exposure, up to 156 weeks, + 84 days safety follow-up.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Any AIN457 150 mg</title>
          <description>1 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
        </group>
        <group group_id="E2">
          <title>Any AIN457 300 mg</title>
          <description>2 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
        </group>
        <group group_id="E3">
          <title>Any AIN457</title>
          <description>Any patients exposed to AIN457</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Matching Placebo at Beseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Inflammatory bowel disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Abscess of salivary gland</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Joint abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Cardiac valve rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Traumatic arthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Follicular thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Invasive papillary breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Lip squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Ovarian cancer stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Phyllodes tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Salivary gland neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Quadriparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Device loosening</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Sopor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Ovarian cyst torsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Uterovaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Nasal turbinate hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="153" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="201" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="320" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="65" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="105" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="406"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

